20:17:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-01-09 08:00:00

Bergen, Norway, January 9th, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has received the official documentation for ISO 13485 certification.

Reference is made to Lifecare’s stock exchange notification 27th of November 2022 when the ISO 13495 audit was conducted, and finalized, at Lifecare Laboratory. This progress is in accordance with the current list of communicated trigger events.

ISO 13485 is a Quality Management System specific to medical devices and covers the entire life cycle of a device, from design and development to production, installation, and servicing. Lifecare’s ISO 13485 certification covers “Development services for manufacturers of medical devices such as CGM devices”.

Lifecare’s ultimate goal to enter the human market is product CE marking. Lifecare has now received ISO 9001 and ISO 13485 certification and thus signed off on two essential steps on the way to product CE mark.

- This was expected, but still incredibly gratifying to receive the confirmation that we are ISO 13485 certified. This is of course a very important step for the company and the organization. I can repeat that I am deeply impressed by how our QMS team in Bergen and Mainz have driven this process forward and finally received the final documentation of their dedication and high standards when it comes to quality management. This confirms a solid fundament for our continued work with regulatory processes, says CEO Joacim Holter at Lifecare.

- Safety, compliance and top-class quality are our unwavering guidelines in our market for medical devices. One thing is that there are demands from the authorities, but ISO certification also means something for the professional integrity of the employees, but also for the credibility of the company, says Senior QMS Manager Barbora Tencer.

According to the International Organization for Standardization (ISO) regulatory requirements are increasingly stringent throughout every step of a product’s life cycle, including service and delivery. Increasingly, organizations in the industry are expected to demonstrate their quality management processes and ensure best practice in everything they do. This internationally agreed standard sets out the requirements for a quality management system specific to the medical devices industry.

In November CEO Joacim Holter commented on the successful audit. - It is vital for the integrity of the production of Sencell Continuous Glucose Monitor, and later commercialization of the product, that our Quality Management System are certified. We depend on the trust from the market and patient groups, that our processes meet international quality standards. It is therefore very motivating to successfully complete the ISO 13485 audit in accordance with the planned and communicated timeline. This is solid confirmation that Lifecares operations are compliant with the standards necessary to develop and produce medical devices. Lifecare will continue to improve our standards and quality systems to ensure regulatory compliance in our upcoming operations.